2017: NIH non-response response to KEI and MSF comments on the proposed exclusive license of Zika vaccine patents to PaxVax

(More on government funded inventions here. Other KEI comments on NIH licenses are found here.)

On November 30, 2017, KEI has received a response from the National Institute of Allergy and Infectious Diseases regarding our previous joint comments with MSFon the proposed exclusive license of Zika vaccine technology to PaxVax.

The original joint comments from KEI and Médecins Sans Frontières (MSF) contained twelve pages of questions and concerns, while a separate submission by KEI alone contained two pages of comments.

The three sentence response from NIAID failed to address any of the issues we discussed, or answer any questions we asked.

The NIAID response, which is really a non-response, is available here.